WS Investor
01 Sep 2026, 14:46
Vertex Completes $10 Billion Crinetics Acquisition, Expanding Into Rare Endocrine Diseases
Vertex Pharmaceuticals (NASDAQ: VRTX) announced Tuesday that it has completed its acquisition of Crinetics Pharmaceuticals, adding a new rare endocrine disease business to its growing portfolio beyond cystic fibrosis.
The transaction values Crinetics at approximately $10 billion in equity value, or about $8.8 billion after accounting for estimated cash acquired. Vertex expects the acquisition to accelerate revenue growth and become accretive to non-GAAP operating income in 2029.
The centerpiece of the deal is PALSONIFY, the first and only once-daily oral therapy for acromegaly. The drug has already launched in the U.S., received approval in Europe and is under regulatory review in additional markets.
Vertex also gains atumelnant, a once-daily oral ACTH receptor antagonist currently in Phase 3 development for congenital adrenal hyperplasia and Phase 2 development for Cushing’s syndrome. Vertex estimates that PALSONIFY and atumelnant could generate more than $5 billion in combined annual revenue at peak.
The acquisition establishes rare endocrine diseases as another major growth pillar for Vertex alongside cystic fibrosis, hematology, acute pain and renal diseases. It also reduces the company’s historical dependence on its highly successful cystic fibrosis franchise.
Vertex separately announced several leadership changes to support its expanding portfolio. Charles Wagner will oversee the Crinetics integration as COO, Jonathan Poole will become CFO on January 1, 2027, and former Amgen executive Jasper van Grunsven will join the company to lead its pain franchise and new product planning.
Vertex Pharmaceuticals (NASDAQ: VRTX) announced Tuesday that it has completed its acquisition of Crinetics Pharmaceuticals, adding a new rare endocrine disease business to its growing portfolio beyond cystic fibrosis.
The transaction values Crinetics at approximately $10 billion in equity value, or about $8.8 billion after accounting for estimated cash acquired. Vertex expects the acquisition to accelerate revenue growth and become accretive to non-GAAP operating income in 2029.
The centerpiece of the deal is PALSONIFY, the first and only once-daily oral therapy for acromegaly. The drug has already launched in the U.S., received approval in Europe and is under regulatory review in additional markets.
Vertex also gains atumelnant, a once-daily oral ACTH receptor antagonist currently in Phase 3 development for congenital adrenal hyperplasia and Phase 2 development for Cushing’s syndrome. Vertex estimates that PALSONIFY and atumelnant could generate more than $5 billion in combined annual revenue at peak.
The acquisition establishes rare endocrine diseases as another major growth pillar for Vertex alongside cystic fibrosis, hematology, acute pain and renal diseases. It also reduces the company’s historical dependence on its highly successful cystic fibrosis franchise.
Vertex separately announced several leadership changes to support its expanding portfolio. Charles Wagner will oversee the Crinetics integration as COO, Jonathan Poole will become CFO on January 1, 2027, and former Amgen executive Jasper van Grunsven will join the company to lead its pain franchise and new product planning.
